

Amendments to the Specification:

Please replace paragraph [0023] with the following rewritten paragraph:

[0023] Five dose levels were used: dose level A was 10 µg of NY-ESO-1 protein in 12 µg ISCOM (3 patients); dose level B was 36 30 µg of the protein in 36 µg ISCOM (3 patients); dose level C was 100 µg of protein in 120 µg ISCOM (16 patients, divided equally between HLA-A2 positive and negative patients), and dose level D was 100 µg NY-ESO-1 without ISCOM (16 patients, equally divided between HLA-A2 positive and negative patients). Randomization was in effect for dose levels C and D, such that four additional patients in each group, equally divided between HLA-A2 positive and negative patients, received sterile saline as placebo.